References
- Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014 Jan 23. [Epub ahead of print]
- Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 2012;91:1861–1870.
- Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362–375.
- Bogenberger JM, Pierceall WE, Lena R, et al. BH3 profiling predicts 5-azacytidine response in malignant myeloid cells. Blood 2012;120(Suppl. 1): Abstract 1432.
- Tibes R, Kornblau SM, Pierceall WE, et al. BH3 profiling as predictor of 5-azacytidine and decitabine clinical responses. Blood 2013;122:603.
- Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564–571.
- Zeuner A, Pedini F, Francescangeli F, et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 2009;113:1522–1525.
- Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012;26:120–125.
- Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005;307:1101–1104.
- Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351–365.
- Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 2013;23:612–619.
- Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31(Suppl.): Abstract 7018.
- Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013;12:329–341.